Concepts (274)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 19 | 2007 | 329 | 1.080 |
Why?
|
| Islets of Langerhans Transplantation | 21 | 2006 | 178 | 0.990 |
Why?
|
| Pancreas Transplantation | 7 | 2007 | 20 | 0.780 |
Why?
|
| Graft Survival | 13 | 2007 | 297 | 0.770 |
Why?
|
| Leukocyte Common Antigens | 10 | 2006 | 59 | 0.750 |
Why?
|
| Plasma Gases | 4 | 2022 | 5 | 0.730 |
Why?
|
| Graft Rejection | 9 | 2004 | 302 | 0.490 |
Why?
|
| Diabetes Mellitus, Experimental | 5 | 2018 | 201 | 0.390 |
Why?
|
| Antibodies, Monoclonal | 7 | 2006 | 870 | 0.370 |
Why?
|
| Bandages | 1 | 2012 | 16 | 0.370 |
Why?
|
| Hemostatics | 1 | 2012 | 27 | 0.370 |
Why?
|
| Warfare | 1 | 2012 | 41 | 0.370 |
Why?
|
| Islets of Langerhans | 12 | 2006 | 280 | 0.340 |
Why?
|
| Tissue Donors | 8 | 2007 | 154 | 0.340 |
Why?
|
| Military Personnel | 1 | 2012 | 120 | 0.330 |
Why?
|
| Hemorrhage | 1 | 2012 | 275 | 0.320 |
Why?
|
| Tissue and Organ Procurement | 4 | 2007 | 44 | 0.300 |
Why?
|
| Wounds and Injuries | 1 | 2012 | 251 | 0.300 |
Why?
|
| Ursidae | 2 | 2020 | 12 | 0.300 |
Why?
|
| Transplantation Tolerance | 3 | 2006 | 69 | 0.270 |
Why?
|
| CD40 Ligand | 4 | 2005 | 159 | 0.270 |
Why?
|
| Transplantation Immunology | 4 | 2005 | 26 | 0.250 |
Why?
|
| Transplantation, Homologous | 10 | 2006 | 249 | 0.230 |
Why?
|
| Bacterial Infections | 2 | 2004 | 153 | 0.210 |
Why?
|
| Immunosuppressive Agents | 6 | 2001 | 381 | 0.210 |
Why?
|
| Neoplasm Proteins | 2 | 2021 | 283 | 0.210 |
Why?
|
| Osteomyelitis | 1 | 2003 | 24 | 0.200 |
Why?
|
| Aspergillosis | 1 | 2003 | 41 | 0.200 |
Why?
|
| Spinal Diseases | 1 | 2003 | 49 | 0.200 |
Why?
|
| Hibernation | 2 | 2020 | 10 | 0.200 |
Why?
|
| Insulin | 10 | 2005 | 686 | 0.200 |
Why?
|
| Breast Neoplasms | 2 | 2022 | 1213 | 0.190 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2022 | 32 | 0.180 |
Why?
|
| Sarcoma | 1 | 2022 | 36 | 0.180 |
Why?
|
| Mice, Inbred BALB C | 9 | 2006 | 891 | 0.180 |
Why?
|
| RNA, Neoplasm | 1 | 2021 | 34 | 0.180 |
Why?
|
| Cholangiocarcinoma | 1 | 2021 | 34 | 0.170 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2022 | 73 | 0.170 |
Why?
|
| Antibodies, Blocking | 1 | 2001 | 39 | 0.170 |
Why?
|
| Antigens, Differentiation | 4 | 2006 | 141 | 0.170 |
Why?
|
| Hemostasis | 1 | 2020 | 18 | 0.160 |
Why?
|
| Chorion | 1 | 2018 | 5 | 0.150 |
Why?
|
| Amnion | 1 | 2018 | 9 | 0.150 |
Why?
|
| Achilles Tendon | 1 | 2018 | 7 | 0.150 |
Why?
|
| Diabetic Nephropathies | 2 | 2004 | 38 | 0.150 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 147 | 0.150 |
Why?
|
| Tendon Injuries | 1 | 2018 | 16 | 0.150 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2018 | 41 | 0.140 |
Why?
|
| Histones | 1 | 2021 | 486 | 0.140 |
Why?
|
| Animals | 27 | 2020 | 20967 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 457 | 0.130 |
Why?
|
| Antibodies | 1 | 1998 | 186 | 0.130 |
Why?
|
| Blood Coagulation | 1 | 2017 | 39 | 0.130 |
Why?
|
| Body Constitution | 1 | 1997 | 16 | 0.130 |
Why?
|
| Histocompatibility Testing | 1 | 1997 | 32 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 10 | 2006 | 3450 | 0.130 |
Why?
|
| Immune Tolerance | 3 | 2005 | 181 | 0.130 |
Why?
|
| RNA, Messenger | 2 | 2021 | 1552 | 0.120 |
Why?
|
| Osteoporosis | 3 | 2002 | 108 | 0.120 |
Why?
|
| Humans | 31 | 2022 | 64283 | 0.120 |
Why?
|
| Immunotherapy | 1 | 1998 | 265 | 0.120 |
Why?
|
| Kidney | 2 | 1997 | 455 | 0.110 |
Why?
|
| Immunoglobulins | 1 | 1994 | 76 | 0.110 |
Why?
|
| Immunization, Passive | 1 | 1994 | 96 | 0.110 |
Why?
|
| Cytomegalovirus Infections | 1 | 1994 | 68 | 0.110 |
Why?
|
| Mice | 14 | 2006 | 11004 | 0.100 |
Why?
|
| Incidence | 5 | 2004 | 1385 | 0.100 |
Why?
|
| RNA, Small Interfering | 3 | 2022 | 930 | 0.100 |
Why?
|
| MicroRNAs | 1 | 2020 | 697 | 0.100 |
Why?
|
| Cytomegalovirus | 1 | 1994 | 94 | 0.100 |
Why?
|
| Ischemia | 1 | 1995 | 196 | 0.100 |
Why?
|
| Time Factors | 8 | 2006 | 3725 | 0.100 |
Why?
|
| Male | 19 | 2020 | 30322 | 0.100 |
Why?
|
| Heart Arrest | 1 | 1995 | 177 | 0.100 |
Why?
|
| Cell Line, Tumor | 3 | 2021 | 1496 | 0.100 |
Why?
|
| Signal Transduction | 3 | 2003 | 3070 | 0.090 |
Why?
|
| Cyclosporins | 4 | 1987 | 17 | 0.090 |
Why?
|
| Postoperative Complications | 3 | 2002 | 1301 | 0.090 |
Why?
|
| Adjuvants, Immunologic | 2 | 2003 | 230 | 0.080 |
Why?
|
| Gene Silencing | 2 | 2020 | 406 | 0.080 |
Why?
|
| Cell Death | 2 | 2022 | 286 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 358 | 0.080 |
Why?
|
| Tissue and Organ Harvesting | 2 | 2007 | 32 | 0.080 |
Why?
|
| Antigens | 2 | 2006 | 149 | 0.070 |
Why?
|
| Apoptosis | 2 | 2022 | 1095 | 0.070 |
Why?
|
| Seasons | 2 | 2020 | 138 | 0.070 |
Why?
|
| Female | 13 | 2022 | 33382 | 0.070 |
Why?
|
| Antilymphocyte Serum | 3 | 1998 | 22 | 0.070 |
Why?
|
| Graft Enhancement, Immunologic | 2 | 2003 | 10 | 0.070 |
Why?
|
| Health Care Rationing | 1 | 2007 | 21 | 0.070 |
Why?
|
| Guidelines as Topic | 1 | 2007 | 158 | 0.060 |
Why?
|
| Acyclovir | 2 | 1997 | 21 | 0.060 |
Why?
|
| Death | 1 | 2006 | 32 | 0.060 |
Why?
|
| Organ Transplantation | 1 | 2007 | 57 | 0.060 |
Why?
|
| Spleen | 2 | 1986 | 483 | 0.060 |
Why?
|
| Middle Aged | 10 | 2007 | 17921 | 0.060 |
Why?
|
| Up-Regulation | 3 | 2020 | 375 | 0.060 |
Why?
|
| Skin Transplantation | 3 | 2005 | 154 | 0.060 |
Why?
|
| Reoperation | 1 | 2007 | 292 | 0.060 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2006 | 114 | 0.060 |
Why?
|
| Rats | 4 | 2018 | 2005 | 0.060 |
Why?
|
| Retrospective Studies | 6 | 1997 | 6740 | 0.060 |
Why?
|
| Bone Diseases, Metabolic | 2 | 2002 | 20 | 0.060 |
Why?
|
| Antigens, CD | 5 | 2006 | 348 | 0.060 |
Why?
|
| Immunoconjugates | 2 | 2003 | 93 | 0.050 |
Why?
|
| CTLA-4 Antigen | 4 | 2006 | 73 | 0.050 |
Why?
|
| Diabetes Mellitus | 2 | 2006 | 541 | 0.050 |
Why?
|
| Dogs | 6 | 1986 | 332 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2005 | 679 | 0.050 |
Why?
|
| Kidney Failure, Chronic | 1 | 2004 | 205 | 0.050 |
Why?
|
| Cell Separation | 1 | 2002 | 146 | 0.050 |
Why?
|
| Alendronate | 1 | 2002 | 14 | 0.050 |
Why?
|
| Blood Glucose | 4 | 1997 | 487 | 0.050 |
Why?
|
| Chronic Disease | 2 | 1997 | 756 | 0.050 |
Why?
|
| Receptors, Progesterone | 1 | 2022 | 110 | 0.040 |
Why?
|
| Living Donors | 2 | 2004 | 78 | 0.040 |
Why?
|
| Leucovorin | 1 | 2021 | 9 | 0.040 |
Why?
|
| Bone Remodeling | 1 | 2001 | 25 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 2022 | 130 | 0.040 |
Why?
|
| Adult | 8 | 2006 | 17134 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2021 | 69 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2021 | 142 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2002 | 2482 | 0.040 |
Why?
|
| Cell Division | 1 | 2022 | 455 | 0.040 |
Why?
|
| Models, Immunological | 1 | 2001 | 86 | 0.040 |
Why?
|
| Antithrombin III | 1 | 2020 | 14 | 0.040 |
Why?
|
| Bone Resorption | 1 | 2000 | 45 | 0.040 |
Why?
|
| Muromonab-CD3 | 2 | 1997 | 7 | 0.040 |
Why?
|
| Oxidation-Reduction | 1 | 2021 | 327 | 0.040 |
Why?
|
| Injections, Intravenous | 3 | 2005 | 156 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2001 | 199 | 0.040 |
Why?
|
| Infection Control | 1 | 2001 | 105 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2001 | 268 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2001 | 467 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 869 | 0.040 |
Why?
|
| Cadaver | 2 | 2004 | 129 | 0.040 |
Why?
|
| Rupture | 1 | 2018 | 24 | 0.040 |
Why?
|
| Hepatocytes | 1 | 2020 | 220 | 0.040 |
Why?
|
| Cell Movement | 1 | 2001 | 466 | 0.040 |
Why?
|
| Monocytes | 1 | 2001 | 357 | 0.040 |
Why?
|
| Pancreatectomy | 4 | 1986 | 104 | 0.040 |
Why?
|
| Creatinine | 2 | 2002 | 133 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2001 | 572 | 0.030 |
Why?
|
| Ganciclovir | 1 | 1997 | 18 | 0.030 |
Why?
|
| Hospitalization | 2 | 1996 | 1368 | 0.030 |
Why?
|
| Lymphoproliferative Disorders | 1 | 1997 | 39 | 0.030 |
Why?
|
| Osteocalcin | 3 | 2002 | 47 | 0.030 |
Why?
|
| Transplantation, Isogeneic | 1 | 1997 | 8 | 0.030 |
Why?
|
| Body Surface Area | 1 | 1997 | 11 | 0.030 |
Why?
|
| Tacrolimus | 1 | 1997 | 64 | 0.030 |
Why?
|
| Cyclosporine | 1 | 1997 | 77 | 0.030 |
Why?
|
| Cytokines | 1 | 2001 | 945 | 0.030 |
Why?
|
| Bone Density | 3 | 2002 | 137 | 0.030 |
Why?
|
| Fluid Therapy | 1 | 1996 | 46 | 0.030 |
Why?
|
| Exons | 1 | 1997 | 201 | 0.030 |
Why?
|
| Thymectomy | 2 | 2006 | 35 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 1997 | 198 | 0.030 |
Why?
|
| Regression Analysis | 1 | 1997 | 498 | 0.030 |
Why?
|
| Acute Disease | 2 | 1998 | 671 | 0.030 |
Why?
|
| Glucose Tolerance Test | 2 | 1986 | 97 | 0.030 |
Why?
|
| Waiting Lists | 2 | 2007 | 56 | 0.030 |
Why?
|
| Regional Blood Flow | 1 | 1995 | 110 | 0.030 |
Why?
|
| Body Weight | 1 | 1997 | 379 | 0.030 |
Why?
|
| Opportunistic Infections | 1 | 1994 | 30 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 1997 | 930 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 1997 | 329 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 1994 | 34 | 0.030 |
Why?
|
| Temperature | 1 | 1995 | 312 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1995 | 625 | 0.030 |
Why?
|
| Kinetics | 1 | 1995 | 766 | 0.030 |
Why?
|
| Virus Diseases | 1 | 1994 | 123 | 0.030 |
Why?
|
| Actuarial Analysis | 1 | 1993 | 17 | 0.020 |
Why?
|
| Morbidity | 1 | 1993 | 111 | 0.020 |
Why?
|
| Abatacept | 2 | 2003 | 66 | 0.020 |
Why?
|
| Communicable Diseases | 1 | 1993 | 91 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2007 | 5696 | 0.020 |
Why?
|
| Risk Factors | 2 | 2004 | 5341 | 0.020 |
Why?
|
| Survival Analysis | 1 | 1993 | 587 | 0.020 |
Why?
|
| Age Factors | 2 | 2007 | 1570 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 2238 | 0.020 |
Why?
|
| Transplantation, Autologous | 3 | 1986 | 125 | 0.020 |
Why?
|
| Preoperative Care | 2 | 1996 | 199 | 0.020 |
Why?
|
| Mice, Inbred NOD | 2 | 2003 | 526 | 0.020 |
Why?
|
| Liver Transplantation | 2 | 2007 | 217 | 0.020 |
Why?
|
| Amino Acids | 2 | 2001 | 148 | 0.020 |
Why?
|
| Mice, Knockout | 2 | 2005 | 2140 | 0.020 |
Why?
|
| Lymphocyte Activation | 2 | 2003 | 761 | 0.020 |
Why?
|
| Length of Stay | 1 | 1993 | 819 | 0.020 |
Why?
|
| Calcium | 2 | 2002 | 580 | 0.020 |
Why?
|
| Cold Ischemia | 1 | 2007 | 3 | 0.020 |
Why?
|
| Glucose | 2 | 1986 | 471 | 0.020 |
Why?
|
| Lung Transplantation | 1 | 2007 | 74 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 1986 | 63 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2007 | 201 | 0.020 |
Why?
|
| Fasting | 1 | 1986 | 51 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2006 | 38 | 0.020 |
Why?
|
| Biomarkers | 2 | 2002 | 1431 | 0.010 |
Why?
|
| Methods | 1 | 2005 | 40 | 0.010 |
Why?
|
| Lymphocyte Transfusion | 1 | 2005 | 37 | 0.010 |
Why?
|
| Postoperative Care | 1 | 1986 | 124 | 0.010 |
Why?
|
| Isoantibodies | 1 | 2005 | 35 | 0.010 |
Why?
|
| Organ Preservation Solutions | 1 | 2005 | 5 | 0.010 |
Why?
|
| Raffinose | 1 | 2005 | 3 | 0.010 |
Why?
|
| Heart Transplantation | 1 | 2007 | 176 | 0.010 |
Why?
|
| Allopurinol | 1 | 2005 | 15 | 0.010 |
Why?
|
| Adolescent | 3 | 2004 | 6305 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1986 | 374 | 0.010 |
Why?
|
| Glutathione | 1 | 2005 | 56 | 0.010 |
Why?
|
| Models, Animal | 1 | 2005 | 240 | 0.010 |
Why?
|
| Adenosine | 1 | 2005 | 78 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2003 | 47 | 0.010 |
Why?
|
| New England | 1 | 2004 | 269 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 2006 | 348 | 0.010 |
Why?
|
| Risk | 1 | 2004 | 379 | 0.010 |
Why?
|
| Coronary Disease | 1 | 2004 | 246 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 402 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2007 | 874 | 0.010 |
Why?
|
| Interleukin-7 | 1 | 2003 | 29 | 0.010 |
Why?
|
| CD3 Complex | 1 | 2003 | 65 | 0.010 |
Why?
|
| Ficoll | 1 | 2002 | 4 | 0.010 |
Why?
|
| Filtration | 1 | 2002 | 20 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 2003 | 167 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2006 | 1297 | 0.010 |
Why?
|
| Base Sequence | 1 | 2005 | 1335 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2003 | 161 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 2002 | 47 | 0.010 |
Why?
|
| Everolimus | 1 | 2001 | 22 | 0.010 |
Why?
|
| Calcineurin Inhibitors | 1 | 2001 | 23 | 0.010 |
Why?
|
| Algorithms | 1 | 2007 | 1029 | 0.010 |
Why?
|
| Infection Control Practitioners | 1 | 2001 | 2 | 0.010 |
Why?
|
| Facility Regulation and Control | 1 | 2001 | 3 | 0.010 |
Why?
|
| Professional Staff Committees | 1 | 2001 | 5 | 0.010 |
Why?
|
| Cell Line | 1 | 2006 | 2057 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2005 | 645 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 2001 | 48 | 0.010 |
Why?
|
| Physician Executives | 1 | 2001 | 28 | 0.010 |
Why?
|
| Italy | 1 | 2001 | 68 | 0.010 |
Why?
|
| Parathyroid Hormone | 1 | 2001 | 44 | 0.010 |
Why?
|
| Sirolimus | 1 | 2001 | 94 | 0.010 |
Why?
|
| Nursing Staff | 1 | 2001 | 40 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2003 | 576 | 0.010 |
Why?
|
| Aged | 3 | 2004 | 14662 | 0.010 |
Why?
|
| Prednisone | 1 | 2000 | 85 | 0.010 |
Why?
|
| Calcineurin | 1 | 2001 | 47 | 0.010 |
Why?
|
| Hypertension | 1 | 2004 | 593 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2006 | 1622 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 2005 | 802 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2004 | 2019 | 0.010 |
Why?
|
| Rabbits | 1 | 1998 | 333 | 0.010 |
Why?
|
| Antigens, CD19 | 1 | 1997 | 25 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2001 | 1272 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1997 | 197 | 0.010 |
Why?
|
| Rats, Inbred Lew | 2 | 1987 | 106 | 0.010 |
Why?
|
| Prognosis | 1 | 2001 | 1769 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 1998 | 744 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1996 | 176 | 0.010 |
Why?
|
| Nephrectomy | 1 | 1996 | 93 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2001 | 1019 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2001 | 800 | 0.010 |
Why?
|
| Child | 1 | 2004 | 4583 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2001 | 3318 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2000 | 2621 | 0.010 |
Why?
|
| United States | 1 | 2007 | 7923 | 0.010 |
Why?
|
| Rats, Inbred ACI | 1 | 1987 | 6 | 0.000 |
Why?
|
| Rats, Inbred BN | 1 | 1987 | 26 | 0.000 |
Why?
|
| Methacholine Compounds | 1 | 1986 | 12 | 0.000 |
Why?
|
| Methacholine Chloride | 1 | 1986 | 23 | 0.000 |
Why?
|
| Vagus Nerve | 1 | 1986 | 21 | 0.000 |
Why?
|
| Portal Vein | 1 | 1986 | 38 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1987 | 251 | 0.000 |
Why?
|
| Electric Stimulation | 1 | 1986 | 139 | 0.000 |
Why?
|
| Combined Modality Therapy | 1 | 1987 | 375 | 0.000 |
Why?
|
| Tissue Preservation | 1 | 1985 | 5 | 0.000 |
Why?
|
| Swine | 1 | 1985 | 395 | 0.000 |
Why?
|